Identifying Rational, Synergistic Neoantigen Combination Strategies to Maximise Clinical Efficacy & Overcome Tumour Resistance to Improve Patient Response Rate
Time: 9:01 am
day: Pre-Conference Day
Details:
Helping the industry to overcome challenges in efficacy and tumour resistance, combination strategies have been hailed the future of immunotherapy, with neoantigen-targeted cell therapies and vaccines increasingly being administered alongside other immunotherapies. However, navigating the complexity of administering multiple drugs requires smart protocol design, identification of distinct biomarkers, careful monitoring of toxicity, and precise assays to elucidate the effect of each therapy.
This workshop will cover:
- Understanding the limitations of neoantigen monotherapies and identifying the most rational, synergistic combination strategies
- How to optimise patient selection based on individual patient and tumour characteristics and immunopeptidomic data
- How to schedule administration, determine dosing, and monitor toxicity in patients to maximise efficacy and tolerability of neoantigen-targeted therapy combinations
- Effectively monitoring immune response and identifying unique biomarkers to elucidate the effect of each individual therapy to determine synergy versus independent action
